Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of roginolisib in uveal melanoma
ISRCTN28449692Phase 2Active, not recruiting
- Sponsor
- iOnctura
- Start
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of roginolisib in intraocular melanoma and eye melanoma, sponsored by iOnctura. Primary endpoint: Overall survival. Started Dec 2024; status: active, not recruiting.
02
Drugs
roginolisib
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on ISRCTN28449692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN28449692.